Vitt Daniel

SEC source: 0001193805-26-000884 · e665604_4-vitt.xml · derivative · entry 1

Vitt Daniel · CIK 0001773673 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 445,000

Underlying: Common Stock · 445,000 shares

Expires 2036-04-02

F1 · shares: Represents options to purchase shares of common stock conditionally approved by the Board of Directors, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026.

F2 · derivative.exercise_date: The shares underlying this option vest 25% on April 2, 2027, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

SEC source: 0001193805-25-001067 · e664707_4-vitt.xml · derivative · entry 5

Vitt Daniel · CIK 0001773673 · Director · CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 860,000

Underlying: Common Stock · 860,000 shares

Expires 2035-07-16

F5 · derivative.exercise_date: Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the third tranche of the January 2024 Offering.

F1 · derivative.underlying: The Stock Appreciation Rights ("SARs") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock.

SEC source: 0001193805-25-001067 · e664707_4-vitt.xml · derivative · entry 4

Vitt Daniel · CIK 0001773673 · Director · CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 860,000

Underlying: Common Stock · 860,000 shares

Expires 2035-07-16

F4 · derivative.exercise_date: Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the second tranche of the Issuer's January 4, 2024 private placement (the "January 2024 Offering").

F1 · derivative.underlying: The Stock Appreciation Rights ("SARs") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock.

SEC source: 0001193805-25-001067 · e664707_4-vitt.xml · derivative · entry 3

Vitt Daniel · CIK 0001773673 · Director · CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,720,000

Underlying: Common Stock · 1,720,000 shares

Expires 2035-07-16

F3 · derivative.exercise_date: Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series B purchase warrants by the holders thereof.

F1 · derivative.underlying: The Stock Appreciation Rights ("SARs") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock.

SEC source: 0001193805-25-001067 · e664707_4-vitt.xml · derivative · entry 2

Vitt Daniel · CIK 0001773673 · Director · CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,720,000

Underlying: Common Stock · 1,720,000 shares

Expires 2035-07-16

F2 · derivative.exercise_date: Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series A purchase warrants by the holders thereof.

F1 · derivative.underlying: The Stock Appreciation Rights ("SARs") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock.

SEC source: 0001193805-25-001067 · e664707_4-vitt.xml · derivative · entry 1

Vitt Daniel · CIK 0001773673 · Director · CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 860,000

Underlying: Common Stock · 860,000 shares

Expires 2035-07-16

F1 · derivative.underlying: The Stock Appreciation Rights ("SARs") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock.

SEC source: 0001193805-25-000821 · e664605_4-vitt.xml · derivative · entry 3

Vitt Daniel · CIK 0001773673 · Director · CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,535,000

Underlying: Common Stock · 1,535,000 shares

Expires 2035-06-05

F3 · derivative.exercise_date: 25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months.

SEC source: 0001193805-25-000923 · e664638_4a-vitt.xml · derivative · entry 3

Vitt Daniel · CIK 0001773673 · Director · CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,558,000

Underlying: Common Stock · 1,558,000 shares

Expires 2035-06-05

F3 · derivative.exercise_date: 25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months.

SEC source: 0001193805-25-000821 · e664605_4-vitt.xml · nonDerivative · entry 1

Vitt Daniel · CIK 0001773673 · Director · CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,000

F1 · price: The purchase was made in Euros and the price was converted into U.S. dollars based on the foreign currency exchange rate as of June 4, 2025 (at Euro 1.00 = U.S. dollar 1.1384).

SEC source: 0001193805-25-000923 · e664638_4a-vitt.xml · nonDerivative · entry 1

Vitt Daniel · CIK 0001773673 · Director · CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,000

F1 · price: The purchase was made in Euros and the price was converted into U.S. dollars based on the foreign currency exchange rate as of June 4, 2025 (at Euro 1.00 = U.S. dollar 1.1384).

SEC source: 0001193805-24-001441 · e664059_4-vitt.xml · derivative · entry 1

Vitt Daniel · CIK 0001773673 · Director · CEO and Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 820,000

Underlying: Common Stock · 820,000 shares

Expires 2034-12-04

F1 · derivative.exercise_date: 25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months.

SEC source: 0001193805-24-000322 · e619336_4-vitt.xml · derivative · entry 6

Vitt Daniel · CIK 0001773673 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 485,000

Underlying: Common Stock · 485,000 shares

Expires not disclosed

F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

F1 · derivative.expiration_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

SEC source: 0001193805-24-000322 · e619336_4-vitt.xml · derivative · entry 5

Vitt Daniel · CIK 0001773673 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2032-06-15

F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

SEC source: 0001193805-24-000322 · e619336_4-vitt.xml · derivative · entry 4

Vitt Daniel · CIK 0001773673 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 215,000 shares

Expires 2032-01-03

F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

SEC source: 0001193805-24-000322 · e619336_4-vitt.xml · derivative · entry 3

Vitt Daniel · CIK 0001773673 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 115,000 shares

Expires 2031-03-01

F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

SEC source: 0001193805-24-000322 · e619336_4-vitt.xml · derivative · entry 2

Vitt Daniel · CIK 0001773673 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 80,000 shares

Expires 2030-07-02

F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

SEC source: 0001193805-24-000322 · e619336_4-vitt.xml · derivative · entry 1

Vitt Daniel · CIK 0001773673 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 65,000 shares

Expires 2029-08-01

F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

SEC source: 0001193805-24-000282 · e619306_4-vitt.xml · nonDerivative · entry 1

Vitt Daniel · CIK 0001773673 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 390,877

F1 · ownership.nature: 14,000 shares of Immunic, Inc. common stock are owned directly by the Reporting Person, and 362,877 shares of Immunic, Inc. common stock are owned by Listrax UG (haftungsbeschrankt). The Reporting Person is Managing Director of Listrax UG and exercises voting and dispositive power over such shares. The spouse of the Reporting Person acquired 14,000 shares of Immunic, Inc. common stock on February 26, 2024.

SEC source: 0001193805-24-000068 · e619198_4-vitt.xml · derivative · entry 1

Vitt Daniel · CIK 0001773673 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,160,000

Underlying: Common Stock · 1,160,000 shares

Expires 2034-01-17

F1 · derivative.exercise_date: 25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months.

SEC source: 0001193805-23-000020 · e618182_4-vitt.xml · derivative · entry 1

Vitt Daniel · CIK 0001773673 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2033-01-01

F1 · derivative.exercise_date: 25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months.

SEC source: 0001193805-22-001602 · e618054_4-vitt.xml · nonDerivative · entry 1

Vitt Daniel · CIK 0001773673 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 376,877

F1 · ownership.nature: 14,000 shares are owned directly by the Reporting Person and 362,877 shares are owned by Listrax UG (haftungsbeschrankt). The Reporting Person is Managing Director of Listrax UG and exercises voting and dispositive power over such shares.

SEC source: 0001193805-22-000968 · e621755_4-vitt.xml · derivative · entry 1

Vitt Daniel · CIK 0001773673 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2032-06-15

F1 · derivative.exercise_date: 25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months.

SEC source: 0001193805-22-000919 · e621729_4-vitt.xml · nonDerivative · entry 1

Vitt Daniel · CIK 0001773673 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 368,877

F1 · ownership.nature: 6,000 shares are owned directly by the Reporting Person and 362,877 shares are owned by Listrax UG (haftungsbeschrankt). The Reporting Person is Managing Director of Listrax UG and exercises voting and dispositive power over such shares.

SEC source: 0001193805-22-000018 · e621197_4-vitt.xml · derivative · entry 1

Vitt Daniel · CIK 0001773673 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,000

Underlying: Common Stock · 215,000 shares

Expires 2032-01-03

F1 · derivative.exercise_date: 25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months.

SEC source: 0001193805-21-001161 · e620866_4-vitt.xml · nonDerivative · entry 1

Vitt Daniel · CIK 0001773673 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 363,877

F1 · ownership.nature: 1,000 shares are owned directly by the Reporting Person and 362,877 shares are owned by Listrax UG (haftungsbeschrankt). The Reporting Person is Managing Director of Listrax UG and exercises voting and dispositive power over such shares.

SEC source: 0001193805-21-000307 · e620342_4-vitt.xml · derivative · entry 1

Vitt Daniel · CIK 0001773673 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,000

Underlying: Common Stock · 115,000 shares

Expires 2031-03-01

F1 · derivative.exercise_date: 25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months.

SEC source: 0001193805-20-000879 · e619799_4-vitt.xml · nonDerivative · entry 2

Vitt Daniel · CIK 0001773673 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 362,877

F1 · shares: These shares were sold pursuant to the Reporting Person's written trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Plan"). The Plan was adopted in connection with certain tax liabilities related to the issuance of shares in the April 2019 exchange transaction between the Issuer (then known as Vital Therapies, Inc.) and Immunic AG.

F2 · ownership.nature: The Reporting Person is Managing Director of Listrax UG (haftungsbeschrankt), which is the record holder of 362,877 shares of common stock of the Issuer, and exercises voting and dispositive power over such shares.

SEC source: 0001193805-20-000879 · e619799_4-vitt.xml · nonDerivative · entry 1

Vitt Daniel · CIK 0001773673 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 364,177

F1 · shares: These shares were sold pursuant to the Reporting Person's written trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Plan"). The Plan was adopted in connection with certain tax liabilities related to the issuance of shares in the April 2019 exchange transaction between the Issuer (then known as Vital Therapies, Inc.) and Immunic AG.

F2 · ownership.nature: The Reporting Person is Managing Director of Listrax UG (haftungsbeschrankt), which is the record holder of 362,877 shares of common stock of the Issuer, and exercises voting and dispositive power over such shares.

SEC source: 0001193805-20-000793 · e619746_4-vitt.xml · derivative · entry 1

Vitt Daniel · CIK 0001773673 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2030-07-01

F1 · derivative.exercise_date: 20,000 of the shares underlying the option (the "Underlying Shares") vest on the one-year anniversary of the grant date. Thereafter, 1,690 of the Underlying Shares vest on the thirteen (13) month anniversary of the grant date, and 1,666 of the Underlying Shares vest on each successive one-month anniversary thereafter for the next thirty five (35) months.

SEC source: 0001193805-19-000700 · e618582_4-vitt.xml · derivative · entry 1

Vitt Daniel · CIK 0001773673 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2029-08-01

F1 · derivative.exercise_date: 16,250 of the options vest on the one-year anniversary of the grant date. Thereafter, 1,360 of the options vest on the thirteen (13) month anniversary of the grant date, and 1,354 of the options vest on each successive one-month anniversary thereafter for the next thirty five (35) months.